No Picture
News

Takeda forecasts $1.7B loss after Shire integration; Flagship’s preclinical biotech Axcella closes IPO with $71M+ haul

? Takeda’s $TAK first set of financial results since consummating its $62 billion acquisition of Shire is in, and it’s giving analysts a negative surprise. Citing costs for integrating the Ireland-based Shire, the Japanese drugmaker forecasts an operat… […]

No Picture
News

BioNTech nabs PhI antibody and a new US base out of bankruptcy; Pfizer wins conditional drug OK

? BioNTech is buying MabVax’s labs $MBVX and a clinical asset out of bankruptcy as the German mRNA company establishes a satellite operation in San Diego. The biotech, which has evidently been kicking around a monster IPO, acquired the bankrupt operati… […]

No Picture
News

Esperion shares surge as FDA waves off panel review; Adaptimmune buoyed by a positive data snapshot

Derek Archila
? Esperion got a 15% bump on its stock price $ESPR this morning after the biotech reported that the FDA had said it didn’t expect to call an advisory panel together to review the newly accepted NDAs for bempedoic acid (BPA) and their bemp… […]

No Picture
News

GSK plans $100M makeover of US manufacturing site; La Jolla Pharma gets a ‘breakthrough’ with late-stage drug

? GSK $GSK announced today that it will be investing $100 million into its facility in Hamilton, MT to expand long-term vaccine manufacturing capabilities. The expansion will boost production capacity of key components of the adjuvant system used in se… […]

No Picture
News

Turning Point unveils $166M IPO; Aquestive’s riluzole film product is accepted for FDA review

? San Diego-based Turning Point Therapeutics has hit the high end of the range it set for their IPO, pricing an upsized set of 9.3 million shares at $18 a pop. They ended up with $166 million raise, which will go a long way to inspiring more industry I… […]

No Picture
News

Lynparza secures third EU nod; Protein degradation biotech grabs $16M launch round from Chinese VCs; Wave shares tumble on trial delay

? Lynparza, the first PARP inhibitor from AstraZeneca $AZN to win US approval in 2014, has secured its third EU approval. The drug won the EMA nod for use patients with germline BRCA1/2-mutations and who have human epidermal growth factor receptor 2 (H… […]

No Picture
News

TKI biotech lays out plans to raise about $125M in IPO; Hookipa sets terms for upsized $100M IPO

? San Diego-based Turning Point Therapeutics has laid out terms for its IPO, planning to sell 7.4 million shares at a range of $16 to $18 a share. Renaissance Capital reports that insiders expect to take about 40% of a total of around $125 million, whi… […]

No Picture
News

Rubius cites some preclinical progress; Xencor scores deal with Astellas; Eidos to restate quarterly filings

? Rubius Therapeutics $RUBY has posted some positive — though preclinical — study results on its red blood cell tech, saying they were able to track a desired immune response using their drugs.The therapies are designed to increase the flow of T cells … […]

No Picture
News

Pfizer takes its option in AnTolRx deal; Secura Bio scores access to $145M for cancer drug launches

? Two-and-a-half years after Pfizer stepped up to seed the biotech startup AnTolRx, the pharma giant has stepped in to take their option on an immune tolerance therapy for Type 1 diabetes. Based on the lab work of Francisco Quintana, a professor of neu… […]

No Picture
News

Pfizer takes its option in AnTolRx deal; Secura Bio scores access to $145M for cancer drug launches

? Two-and-a-half years after Pfizer stepped up to seed the biotech startup AnTolRx, the pharma giant has stepped in to take their option on an immune tolerance therapy for Type 1 diabetes. Based on the lab work of Francisco Quintana, a professor of neu… […]